Late Breaking Abstract - PMG1015 demonstrates well-tolerated safety and favorable FVC changes after 12 weeks of treatment in IPF Patients - Amsterdam 2025

Translational science in interstitial lung disease 2

Chair(s): Anne-Marie Russell, Maria Hollmén

Session type: Poster session

Late Breaking Abstract - PMG1015 demonstrates well-tolerated safety and favorable FVC changes after 12 weeks of treatment in IPF Patients

Toby M Maher

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

UL ameliorates lung inflammation and pulmonary fibrosis by regulating the TGF-?/T?Rs signaling and autophagy

Wei-chung Chiou

Poster

Abstract

Inhibition of ogg1 a novel strategy for treating pulmonary fibrosis OXC-201 reduces inflammation and fibrosis, leading to improved lung function in mice

Sandra Ekstedt

Poster

Abstract

B Cell Dysregulation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Dong-woo Han

Poster

Abstract

LPCAT1 as a Therapeutic Target for AT2 Regeneration in IPF

Anas Rabata

Poster

Abstract

AT2R agonists buloxibutid (Compound 21) and NAc inhibit fibrogenesis in human precision cut lung slices ex vivo

Olivia Young

Poster

Abstract

Characterization of Human Precision Cut Lung Slices as an ex vivo model for Idiopathic Pulmonary Fibrosis

Gessica Marchini

Poster

Abstract

Macrophage Fra-2 Promotes Pulmonary Inflammation and Fibrosis in a Mouse Model of Pulmonary Interstitial Fibrosis

Yun Liu

Abstract

The efficacy of Frankenia pulverulenta for the treatment of experimental lung fibrosis induced by Bleomycin in Wistar rats

Sana Bahri

Abstract

Advancing pulmonary fibrosis Treatment: Efficacy testing for new drug candidates on the ILD on-chip model

Ferdinand Ativon

Poster

Abstract

Tissue repair response in Non-Specific Interstitial Pneumonia compared to Idiopathic Pulmonary Fibrosis

Vijay Hadda

Poster

Abstract

Ganoderma microsporum immunomodulatory protein (GMI) ameliorates pulmonary fibrosis by regulating the PI3K/Akt/mTOR signaling

Tzu-lan Hsia

Poster

Abstract

A Vaccine Therapy for Idiopathic Pulmonary Fibrosis

Tianxia Lan

Abstract

PMEPA1 regulates the function of fibroblast through STAT3/p-STAT3/GLUT1 pathway to participate in the pathogenesis of IPF

Li Zhen

Abstract

Repositioning a drug for hyperlipidemia as a potential senotherapeutic for aging-related respiratory diseases

Sachi Matsubayashi-hosokawa

Poster

Abstract

The synergistic effects of pirfenidone and PPAR-alpha agonists in alleviating the profibrotic response in pulmonary fibrosis

Gani Oruqaj

Poster

Abstract

Evaluation of a PDGFR?-specific vector for targeted drug delivery in pulmonary fibrosis

Jan Willem Duitman

Poster

Abstract

Exploring the role of hypusine signaling in IPF

Sarah-eve Lemay

Poster

Abstract

The novel autotaxin inhibitor, 2-carba cyclic phosphatidic acid ameliorates bleomycin-induced lung fibrosis in mice.

Keiko Haji

Poster

Abstract

Cluster analysis of cytokines in bronchoalveolar lavage samples from patients with Interstitial Lung Diseases: an exploratory study

Joel Francesqui

Poster

Abstract

Late Breaking Abstract - PMG1015 demonstrates well-tolerated safety and favorable FVC changes after 12 weeks of treatment in IPF Patients

Toby M Maher

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}